Status:
COMPLETED
Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Atherosclerotic Vascular Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the utility of 18Fluorine Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) as a tool to quantify atherosclerotic plaque.
Eligibility Criteria
Inclusion
- Male or Female ages 30 to 80
- Participant is on a low dose statin for at least 6 weeks prior to screening or is statin-naive at screening
Exclusion
- Participant has human immunodeficiency virus (HIV), Hepatitis B or C
- Participant uses illegal drugs
- Participant has Type I diabetes
- Participant has a history of claustrophobia
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00703261
Start Date
August 1 2008
End Date
December 1 2009
Last Update
October 9 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.